DIRS.INFO The most relevant business & tech news

☆ The sectors — and stocks — to buy in Asia after Trump's win, according to analysts
▼ + stars: | 2024-11-08 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

Former U.S. President Donald Trump's victory over Vice President Kamala Harris in this week's election has raised questions about how Asia will be impacted. "When passed, the [tariffs] will sweep across Asia, particularly China [and] should spike volatility and compress multiples as uncertainty prevails." Even so, the analysts say the region is "more prepared than in 2016" and investment opportunities remain, especially given the weaker yen and stimulus in China. This will bring about "structural shifts in global supply chain ... [and] could boost infrastructure spending in ASEAN and South Asia," he added. The currency has fallen versus the dollar following Trump's win, hitting 154.7 per dollar on Wednesday — its weakest level since July 30.

Persons: Donald Trump's, Kamala Harris, India's, Hong, Tai Hui, Hui, Stocks, — CNBC's Lim Hui Jie Organizations: U.S, Trump, Macquarie Research, Nikkei, Dow Jones, Nasdaq, Morgan Asset Management, Congress, Mitsubishi Electric, Mitsubishi, Japanese pharma, Chugai Pharmaceutical, SK Hynix Locations: Asia, China, ASEAN, South Asia, U.S, Macquarie, Japan

☆ This new weight loss drug ETF bets big on two of the industry's leading players
▼ + stars: | 2024-05-27 | by ( Anna Gleason | ) www.cnbc.com time to read: +1 min

A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs. Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF, per Roundhill's website as of Friday. Mazza waived concerns that investors have missed out on the rally, noting the weight loss drug industry is still in its "early days." After last Tuesday's launch, shares of Roundhill's GLP-1 & Weight Loss ETF ended the week down by almost 2%.

Persons: Eli Lilly, Dave Mazza, Mazza, CNBC's Organizations: Investments, Novo Nordisk, Zealand Pharma, Amgen, Chugai Pharmaceutical Locations: Roundhill's

☆ Want to cash in on the weight-loss drug boom? Morgan Stanley names 4 global stocks
▼ + stars: | 2024-02-01 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

Under-the-radar stock picks Morgan Stanley reckons the way to play the obesity theme in Asia is through names involved in GLP-1 drug development that "could find upside in burgeoning overseas markets." Calling it "top beneficiary as global demand for GLP-1 drugs significantly outpaces capacity," Morgan Stanley has an overweight rating on the stock. Morgan Stanley has an investment horizon of just over six months for WuXi AppTec and Innovent and over 12 months for Chugai and EBOS. Morgan Stanley's analysts estimate that worldwide sales of Orforglipron could hit $7 billion in 2023. Elsewhere, it sees opportunities for EBOS following the Australian government's approval for it to distribute obesity drugs.

Persons: Eli Lilly, Morgan, Sean Wu, Morgan Stanley's, Health Organization's, Morgan Stanley, Chugai, Goldman, EBOS, CNBC's Michael Bloom Organizations: Novo Nordisk, Health, WHO, BMI, WuXi AppTec, Australian, Hong Kong Stock Exchange, China Health Care, Goldman Sachs, Health Care Equity, Zealand ETF Locations: U.S, Asia, Asia Pacific, Australia, GLP, WuXi, China, Japan, New Zealand, Zealand

Search resuls for: "Chugai"

3 mentions found